Multiple Myeloma Research Foundation CoMMPass Study


At a Glance
  • Status: Active Consortium
  • Year Launched: 2011
  • Initiating Organization: Multiple Myeloma Research Foundation
  • Initiator Type: Nonprofit foundation
  • Rare disease
  • Disease focus:
    Multiple Myeloma
  • Location: North America

Abstract

The Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) study is an initiative of the Multiple Myeloma Research Foundation’s (MMRF) Personalized Medicine Initiative and aims to discover the molecular and genetic changes behind multiple myeloma in hopes of better defining patient subgroups. As a partnership between 17 academic centers, five pharmaceutical companies, and the U.S. Department of Veterans Affairs (VA), the goal of this eight-year study is to create a database that can accelerate future clinical trials and personalized treatment strategies.

Mission

As part of MMRF’s Personalized Medicine Initiative, the CoMMpass study aims to discover biomarkers that can better define the biological basis of multiple myeloma to help stratify patients.  This effort hopes to obtain samples from approximately 1,000 multiple myeloma patients and follow them over time to identify how a patient’s genetic profile is related to clinical progression and treatment response.

The CoMMpass study has the following goals:

  • Create a guide to which treatments work best for specific patient subgroups

  • Share data with researchers to accelerate drug development for specific subtypes of multiple myeloma patients

Consortium History

MMRF was founded in 1998 by twin sisters Kathy Giusti and Karen Andrews, after Kathy was diagnosed with multiple myeloma.

2004: The Multiple Myeloma Research Consortium (MMRC) was founded as MMRF’s first clinical network. The purpose of this consortium was to bring together leading academic centers solely dedicated to Phase I and Phase II myeloma clinical trials. 

2004: The MMRC Tissue Bank was established to provide researchers with access to bone marrow aspirate and matched peripheral blood samples.

2006: MMRF launched the Multiple Myeloma Genomics Initiative (MMGI) to identify the druggable genes and pathways in myeloma.

2007: MMRC launched the Multiple Myeloma Genomics Portal, an open-access, myeloma-specific repository of genomic data.

2009: MMGI finished mapping the myeloma genome of 100 patients. As of 2013, more than 900 researchers across the globe have accessed these data.

2011: The Personalized Medicine Initiative was initiated to create tools that match myeloma patients with treatments specific to their individual molecular profiles. The CoMMpass study is part of this effort and, as of 2013, has screened more than 200 patients over a network of 50 clinical centers.

2012: MMRF entered into a public-private partnership with the VA through the CoMMpass study.

MMRF was instrumental in the launch of six new U.S. Food and Drug Administration (FDA)–approved multiple myeloma drugs and set into motion 45 new clinical trials. According MMRC, its sponsored trials begin 60 percent faster and patients are enrolled in clinical trials 10 percent faster than the industry standard. MMRC clinical trials currently have eight drug studies entering the last steps before FDA approval.

Structure & Governance

The MMRF founders, Kathy Giusti and Karen Andrews, remain actively involved in the foundation. The governance structure consists of:

  • The Board of Directors is composed of experts in medicine, science, business, and law who provide strategic guidance and oversight.

  • The Executive Committee provides expertise in all aspects of drug discovery and development.

  • The Honorary Board of Directors is composed of high-profile celebrities who endorse MMRF’s activities.

  • The Leadership Council is composed of external business leaders who provide expertise and resources.

  • The Technology Board is composed of leaders who provide guidance in advancing the research portfolio.

MMRF operates as a hub-and-spoke model, where there is central management, operating principles, and parameters that govern and provide oversight to a distributed laboratory network. This ensures that the resources, expertise, and strengths of each individual research institution are leveraged to accelerate the study. Operational management of the CoMMpass study is by co-principal investigators from an academic research institution and a member of the MMRF staff. The participating clinical sites have on-site staff who specialize in myeloma.

Financing

MMRF assets for 2011 were greater than $26 million, composed of private foundation grants (27 percent), revenue from events (28 percent), healthcare corporate donations (33 percent), and individual contributions (8 percent). A precompetitive, consortium-based fund was established to support the CoMMpass study, which includes approximately 50 percent industry funding and 50 percent patient funds from MMRF.

Intellectual Property

CoMMpass is based on an open data access model, and therefore participating academic and pharmaceutical industry partners release their data to the public. The partners have created a patent-free/intellectual-property free zone within the collaboration in which study partners are allowed a several-month period of data exclusivity.

Data Sharing

In order to facilitate discoveries and development related to targeted therapies, the comprehensive data from CoMMpass is placed in an open-access research portal. The data will be part the MMRF Personalized Medicine Platform, which will combine CoMMpass data with those collected from MMRF’s Genomics Initiative. It is hoped that the longitudinal data, combined with the annotated bio-specimens, will help provide insights that can accelerate personalized therapies. 

Points of Contact

Walter Capone

email: caponew@themmrf.org

Ann Quinn Young

email: quinnyounga@themmrf.org

Sponsors & Partners

The CoMMpass study includes more than two dozen clinical sites, industry partners, contract research organizations, and technology-based organizations.

Amgen/Onyx Pharmaceuticals

Atlanta Cancer Care

Barbara Ann Karmanos Cancer Institute

Bay Area Cancer Research Group, LLC

Baylor Research Institute

Billings Clinic

Bristol-Myers Squibb

Broome Oncology

Cancer Care Centers of South Texas

Cancer Care Northwest

Cancer Center of Kansas

Carl & Dorothy Bennett Cancer Center

Dana-Farber Cancer Institute

Dartmouth-Hitchcock Medical Center

East Carolina University

Emory University

Gabrail Cancer Center

GenoSpace

Grand Rapids Clinical Oncology Program

Hackensack University Medical Center

Hematology Oncology Clinic

Hutchinson Clinic

Illinois Cancer Specialists

Johnson & Johnson/Janssen Pharmaceuticals

Maimonides Cancer Center

Marshfield Clinic

Mayo Clinic College of Medicine

Medical Associates of Brevard

Millennium/Takeda Oncology Group

Mount Sinai School of Medicine

Northwest Cancer Specialists

Ocala Oncology Center

Oregon Health and Sciences University

Providence St. Mary Regional Cancer Center

Rockwood Clinic, PS

Rocky Mountain Cancer Centers

Sarah Cannon Research Institute

Sciode Medical Associates

Sharp Memorial Hospital

Tennessee Oncology

Texas Oncology

The Baton Rouge Clinic, AMC

U.S. Department of Veterans Affairs

University of California, San Francisco

University of Chicago

University of Nebraska

University of Southern California

Virginia Cancer Specialists, PC

Washington University

Waverly Hematology Oncology

Weill Cornell Medical College

Yakima Valley Memorial Hospital


Last Updated: 05/24/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.